Trial Profile
Effects of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Sep 2017
Price :
$35
*
At a glance
- Drugs Eplerenone (Primary)
- Indications Primary hyperparathyroidism
- Focus Therapeutic Use
- Acronyms EPATH
- 20 Aug 2017 Results of cross-sectional relationship between parathyroid hormone and cardiovascular parameters (n=76) published in the Journal of Clinical Hypertension (Greenwich)
- 27 Jun 2017 Results published in the Clinical Chemistry and Laboratory Medicine
- 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association